Overview

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

Status:
Terminated

Trial end date:
2017-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or previously treated with an acetylcholinesterase inhibitor.

Phase:

Phase 3

Details

Lead Sponsor:

FORUM Pharmaceuticals Inc

Treatments:

Cholinesterase Inhibitors